Purpose: To investigate the dosimetric feasibility of linear accelerator-based intensity-modulated total marrow irradiation (IM-TMI) in patients with hematologic malignancies.
Methods And Materials: Linear accelerator-based IM-TMI treatment planning was performed for 9 patients using the Eclipse treatment planning system. The planning target volume (PTV) consisted of all the bones in the body from the head to the mid-femur, except for the forearms and hands. Organs at risk (OAR) to be spared included the lungs, heart, liver, kidneys, brain, eyes, oral cavity, and bowel and were contoured by a physician on the axial computed tomography images. The three-isocenter technique previously developed by our group was used for treatment planning. We developed and used a common dose-volume objective method to reduce the planning time and planner subjectivity in the treatment planning process.
Results: A 95% PTV coverage with the 99% of the prescribed dose of 12 Gy was achieved for all nine patients. The average dose reduction in OAR ranged from 19% for the lungs to 68% for the lenses. The common dose-volume objective method decreased the planning time by an average of 35% and reduced the inter- and intra- planner subjectivity.
Conclusion: The results from the present study suggest that the linear accelerator-based IM-TMI technique is clinically feasible. We have demonstrated that linear accelerator-based IM-TMI plans with good PTV coverage and improved OAR sparing can be obtained within a clinically reasonable time using the common dose-volume objective method proposed in the present study.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijrobp.2010.06.029 | DOI Listing |
Cancers (Basel)
January 2025
Istituto Nazionale di Fisica Nucleare, Sezione di Bari, 70125 Bari, Italy.
Background: Boron neutron capture therapy (BNCT) is an innovative binary form of radiation therapy with high selectivity towards cancer tissue based on the neutron capture reaction B(n,α)Li, consisting in the exposition of patients to neutron beams after administration of a boron compound with preferential accumulation in cancer cells. The high linear energy transfer products of the ensuing reaction deposit their energy at the cell level, sparing normal tissue. Although progress in accelerator-based BNCT has led to renewed interest in this cancer treatment modality, in vivo dose monitoring during treatment still remains not feasible and several approaches are under investigation.
View Article and Find Full Text PDFAppl Radiat Isot
January 2025
Kyoto University Graduate School of Engineering, Kyoto Daigaku-katsura, Nishikyo-ku, Kyoto, 615-8530, Japan.
We aimed to explore the possibility of realizing a beam shaping assembly (BSA) driven by a 15-kW beam of 33-MeV electrons of an electron linear accelerator (LINAC) when a boronophenylalanine is adopted as a boron carrier. Simulation calculations were performed to design two types of BSAs driven by the small LINAC. The one was an experimental BSA, and the other was a high-performance BSA.
View Article and Find Full Text PDFFront Oncol
November 2024
Department of Radiation Oncology, Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
Objective: To assess the efficacy and safety of linear accelerator-based fractionated stereotactic radiotherapy (LINAC-FSRT) in patients with brain metastases (BM).
Methods: We retrospectively analyzed 214 patients treated with LINAC-FSRT, categorized based on biologically effective dose (BED10, / = 10) into two groups (≤55 Gy, >55 Gy). Stratified analyses were conducted based on targeted therapy to compare survival outcomes.
J Appl Clin Med Phys
December 2024
Department of Radiation Oncology, Willis Knighton Cancer Center, Shreveport, Louisiana, USA.
Linear accelerator (LINAC)-based stereotactic radiosurgery (SRS) has become a mainstay in the management of intracranial tumors. However, the high fractional doses and sharp gradients used in SRS place heavy demands on geometric accuracy. Image guidance systems such as ExacTrac (ETX, Brainlab AG, Munich, Germany) have been developed to facilitate position verification at nonzero table angles.
View Article and Find Full Text PDFSci Rep
November 2024
Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Iranian Blood Transfusion Organization Building, Next to the Milad Tower, Hemmat Exp. Way, P.O.Box:14665-1157, Tehran, Iran.
X-irradiation of blood products is an alternative for gamma-ray to prevent post-transfusion GvHD. However, commercial X-irradiators are not widely available while little is known about their safety and efficacy for platelet products. This study introduces an efficient, accessible and cost-effective "X irradiation system" for platelet concentrates (PCs).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!